DE69223284D1 - Methoden zur Bestimmung von Krebsmetastasen mittels Nukleinsäuren-Amplifikation - Google Patents

Methoden zur Bestimmung von Krebsmetastasen mittels Nukleinsäuren-Amplifikation

Info

Publication number
DE69223284D1
DE69223284D1 DE69223284T DE69223284T DE69223284D1 DE 69223284 D1 DE69223284 D1 DE 69223284D1 DE 69223284 T DE69223284 T DE 69223284T DE 69223284 T DE69223284 T DE 69223284T DE 69223284 D1 DE69223284 D1 DE 69223284D1
Authority
DE
Germany
Prior art keywords
determination
methods
nucleic acid
acid amplification
cancer metastases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69223284T
Other languages
English (en)
Other versions
DE69223284T2 (de
Inventor
Mark R Green
Ernest S Kawasaki
Robert E Sobol
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
University of California
Original Assignee
F Hoffmann La Roche AG
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24892478&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69223284(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG, University of California filed Critical F Hoffmann La Roche AG
Publication of DE69223284D1 publication Critical patent/DE69223284D1/de
Application granted granted Critical
Publication of DE69223284T2 publication Critical patent/DE69223284T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE69223284T 1991-06-26 1992-06-25 Methoden zur Bestimmung von Krebsmetastasen mittels Nukleinsäuren-Amplifikation Revoked DE69223284T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72006191A 1991-06-26 1991-06-26

Publications (2)

Publication Number Publication Date
DE69223284D1 true DE69223284D1 (de) 1998-01-08
DE69223284T2 DE69223284T2 (de) 1998-06-25

Family

ID=24892478

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69223284T Revoked DE69223284T2 (de) 1991-06-26 1992-06-25 Methoden zur Bestimmung von Krebsmetastasen mittels Nukleinsäuren-Amplifikation

Country Status (9)

Country Link
US (2) US5543296A (de)
EP (1) EP0520794B1 (de)
JP (1) JP3898233B2 (de)
AU (1) AU662906B2 (de)
CA (1) CA2072314C (de)
DE (1) DE69223284T2 (de)
DK (1) DK0520794T3 (de)
ES (1) ES2111047T3 (de)
GR (1) GR3026153T3 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU662906B2 (en) * 1991-06-26 1995-09-21 F. Hoffmann-La Roche Ag Methods for detection of carcinoma metastases by nucleic acid amplification
CA2148350A1 (en) * 1992-10-29 1994-05-11 Carlo Croce Methods of detecting micrometastasis of prostate cancer
US5674682A (en) * 1992-10-29 1997-10-07 Thomas Jefferson University Nucleic acid primers for detecting micrometastasis of prostate cancer
US5641672A (en) * 1993-06-09 1997-06-24 The Trustees Of Columbia University In The City Of New York Cloning and uses of the genetic locus bcl-6
US5601990A (en) * 1994-09-13 1997-02-11 Thomas Jefferson University Methods of diagnosing colorectal tumors and metastasis thereof
US5561041A (en) * 1993-11-12 1996-10-01 The Johns Hopkins University School Of Medicine Nucleic acid mutation detection by analysis of sputum
US6235470B1 (en) 1993-11-12 2001-05-22 The Johns Hopkins University School Of Medicine Detection of neoplasia by analysis of saliva
US6025127A (en) * 1994-01-14 2000-02-15 The Johns Hopkins University School Of Medicine Nucleic acid mutation detection in histologic tissue
EP0760006A1 (de) * 1994-04-15 1997-03-05 The Trustees Of Columbia University In The City Of New York Verfahren zur einstufung von prostatakrebs auf molekularer basis
AU4897896A (en) * 1995-01-04 1996-07-24 Trustees Of Boston University Primers for the pcr amplification of metastatic sequences
AU5310296A (en) * 1995-03-17 1996-10-08 John Wayne Cancer Institute Detection of melanoma or breast metastases with a multiple marker assay
EP0904397A4 (de) * 1996-04-16 2003-01-29 Smithkline Beecham Corp Methode zur erkennung des prostat-spezifischen antigens zur überwachung und diagnose von prostatkrebs
WO1998006736A1 (en) * 1996-08-14 1998-02-19 Life Technologies, Inc. Stable compositions for nucleic acid amplification and sequencing
US6287822B1 (en) 1997-08-05 2001-09-11 Transgenomic, Inc. Mutation detection method
EP0960214A4 (de) * 1996-12-06 2004-08-04 Urocor Inc Diagnose des Krankheitszustandesan HAnd von mRNA-Profilen
US7332270B1 (en) 1997-03-24 2008-02-19 Urocor, Inc. Diagnosis of disease state using mRNA profiles in peripheral leukocytes
US6190857B1 (en) * 1997-03-24 2001-02-20 Urocor, Inc. Diagnosis of disease state using MRNA profiles in peripheral leukocytes
CA2286304C (en) 1997-04-10 2007-08-07 Diagnocure Inc. Pca3, pca3 genes, and methods of use
US6300088B1 (en) 1997-11-24 2001-10-09 Duke University Method of detecting prostate specific antigen
DE19813788A1 (de) * 1998-03-27 1999-10-07 Deutsches Krebsforsch Nachweisverfahren für Tumorzellen
AU3762699A (en) * 1998-04-27 1999-11-16 Pacific Northwest Cancer Foundation (nr-cam) gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors
US6830886B1 (en) * 1998-06-10 2004-12-14 Memorec Medical Molecular Research Cologne Stoffel Gmbh Supports for the parallel identification and transcription profiling of polynucleic acids
EP1100903A1 (de) * 1998-07-24 2001-05-23 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Pb 39, ein dysreguliertes gen in prostatakrebs und deren verwendung
US7226731B1 (en) 1998-07-24 2007-06-05 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services PB 39, a gene dysregulated in prostate cancer, and uses thereof
US6455692B1 (en) 1998-08-04 2002-09-24 Transgenomic, Inc. Method of concentrating polynucleotides using MIPC
US6586176B1 (en) * 1998-08-07 2003-07-01 Cellay, Llc Gel microdrops in genetic analysis
WO2000044940A2 (en) 1999-01-28 2000-08-03 Gen-Probe Incorporated Nucleic acid sequences for detecting genetic markers for cancer in a biological sample
EP1222266B1 (de) 1999-09-29 2006-03-29 Diagnocure Inc. Pca3 mrna in gutartigen und bösartigen prostatageweben
US6203992B1 (en) 1999-10-15 2001-03-20 Abbott Laboratories Nucleic acid primers and probes for detecting tumor cells
US6902890B1 (en) * 1999-11-04 2005-06-07 Diadexus, Inc. Method of diagnosing monitoring, staging, imaging and treating cancer
WO2001034837A1 (en) * 1999-11-12 2001-05-17 Limeart Limited Diagnosis and prognosis of cancer through detection of the tumor antigen 17-1a by rt-pcr
CA2404431C (en) * 2000-03-27 2011-06-07 Thomas Jefferson University Guanylyl cyclase c in the detection of stomach and esophageal cancers
EP1301624A2 (de) * 2000-03-31 2003-04-16 Ludwig Institute For Cancer Research Preprocalcitonin als tumorabstossungsantigenvorläufer und verwendungen davon
US7829276B2 (en) * 2000-09-18 2010-11-09 Thomas Jefferson University Methods of using CRCA-1 as a stomach and esophageal cancer marker
US6897024B2 (en) 2001-05-31 2005-05-24 Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
US7507528B2 (en) 2001-09-06 2009-03-24 Adnagen Ag Method and diagnosis kit for selecting and or qualitative and/or quantitative detection of cells
US8980568B2 (en) 2001-10-11 2015-03-17 Aviva Biosciences Corporation Methods and compositions for detecting non-hematopoietic cells from a blood sample
US8986944B2 (en) 2001-10-11 2015-03-24 Aviva Biosciences Corporation Methods and compositions for separating rare cells from fluid samples
EP1448792A1 (de) * 2001-11-22 2004-08-25 Adnagen AG Diagnose-kit, dns-chip sowie verfahren zur diagnostik oder behandlungskontrolle bei hodenkrebs
US7026120B2 (en) * 2002-04-15 2006-04-11 Abbott Laboratories Probes for detecting tumor cells
GR1004303B (el) * 2002-11-05 2003-07-30 Ελευθεριος Γεωργακοπουλος ΝΕΑ ΜΕΘΟΔΟΣ ΑΝΙΧΝΕΥΣΗΣ ΤΟΥ ΚΑΡΚΙΝΙΚΟΥ ΜΕΜΒΡΑΝΙΚΟΥ ΑΝΤΙΓΟΝΟΥ Ep-Cam ΚΑΙ ΠΡΟΣΔΙΟΡΙΣΜΟΣ ΚΥΚΛΟΦΟΡΟΥΝΤΩΝ ΜΙΚΡΟΜΕΤΑΣΤΑΤΙΚΩΝ ΚΑΡΚΙΝΙΚΩΝ ΚΥΤΤΑΡΩΝ ΣΤΟ ΠΕΡΙΦΕΡΙΚΟ ΑΙΜΑ ΑΣΘΕΝΩΝ (ΚΑΙ ΣΕ ΙΣΤΟΥΣ) ΜΕ ΚΑΡΚΙΝΟ ΕΠΙΘΗΛΙΑΚΗΣ ΠΡΟΕΛΕΥΣΗΣ
US8039218B2 (en) 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
AU2003290925A1 (en) * 2002-11-14 2004-06-15 John Wayne Cancer Institute Detection of micro metastasis of melanoma and breast cancer in paraffin-embedded tumor draining lymph nodes by multimaker quantitative rt-pcr
CA2513780C (en) 2003-02-07 2014-12-30 Diagnocure Inc. Method to detect prostate cancer from a urine sample
US7820030B2 (en) 2003-04-16 2010-10-26 Handylab, Inc. System and method for electrochemical detection of biological compounds
EP1771563A2 (de) 2004-05-28 2007-04-11 Ambion, Inc. VERFAHREN UND ZUSAMMENSETZUNGEN MIT MicroRNA
ES2301268B1 (es) * 2004-10-25 2009-05-01 Centro De Investigacion Biomolecular Aplicada Salamanca, S.L. Empleo del gen slug, o de sus productos de replicacion, transcripcion o expresion, en la identificacion, diagnostico, prevencion o tratamiento de la diseminacion del cancer y/o desarrollo de metastasis.
ES2534304T3 (es) * 2004-11-12 2015-04-21 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
US20060189893A1 (en) * 2005-01-06 2006-08-24 Diamics, Inc. Systems and methods for detecting abnormal cells
US20060161076A1 (en) * 2005-01-06 2006-07-20 Diamics, Inc. Systems and methods for collection of cell clusters
US20070292882A1 (en) * 2006-06-16 2007-12-20 Sysmex Corporation Method and apparatus for detecting cancer cell
CA2657621A1 (en) 2006-07-14 2008-01-17 Aviva Biosciences Corporation Methods and compositions for detecting rare cells from a biological sample
US20080131878A1 (en) * 2006-12-05 2008-06-05 Asuragen, Inc. Compositions and Methods for the Detection of Small RNA
EP2104734A2 (de) * 2006-12-08 2009-09-30 Asuragen, INC. Mir-20-regulierte gene und pfade als ziele für therapeutische interventionen
US20090092974A1 (en) * 2006-12-08 2009-04-09 Asuragen, Inc. Micrornas differentially expressed in leukemia and uses thereof
US20090175827A1 (en) * 2006-12-29 2009-07-09 Byrom Mike W miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090232893A1 (en) * 2007-05-22 2009-09-17 Bader Andreas G miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
CA2689974A1 (en) * 2007-06-08 2008-12-18 Asuragen, Inc. Mir-34 regulated genes and pathways as targets for therapeutic intervention
WO2009036332A1 (en) 2007-09-14 2009-03-19 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
US20090186015A1 (en) * 2007-10-18 2009-07-23 Latham Gary J Micrornas differentially expressed in lung diseases and uses thereof
WO2009070805A2 (en) 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
WO2009126726A1 (en) * 2008-04-08 2009-10-15 Asuragen, Inc Methods and compositions for diagnosing and modulating human papillomavirus (hpv)
EP2990487A1 (de) 2008-05-08 2016-03-02 Asuragen, INC. Zusammensetzungen und verfahren in zusammenhang mit der mirna-modulation von neovaskularisation oder angiogenese
JP5585811B2 (ja) * 2009-01-23 2014-09-10 国立大学法人金沢大学 肺癌、肺癌合併ｌｅｍｓ及びｌｅｍｓの検査方法
WO2013040251A2 (en) 2011-09-13 2013-03-21 Asurgen, Inc. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
KR101762340B1 (ko) 2015-12-09 2017-07-27 주식회사 포스코 수지 조성물 및 이를 이용한 흑색 수지 강판, 및 그 제조방법
GB201802312D0 (en) * 2018-02-13 2018-03-28 Vib Vzw Melanoma disease stratification

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5085983A (en) * 1988-08-19 1992-02-04 City Of Hope Detection of human tumor progression and drug resistance
US5024934A (en) * 1988-03-14 1991-06-18 The Board Of Regents, The University Of Texas System Detection of minimal numbers of neoplastic cells carrying DNA translocations by DNA sequence amplification
US5057410A (en) * 1988-08-05 1991-10-15 Cetus Corporation Chimeric messenger RNA detection methods
DK0506889T3 (da) * 1989-12-22 1997-09-22 Hoffmann La Roche Reverse transkriptaser ved høj temperatur
AU662906B2 (en) * 1991-06-26 1995-09-21 F. Hoffmann-La Roche Ag Methods for detection of carcinoma metastases by nucleic acid amplification

Also Published As

Publication number Publication date
EP0520794B1 (de) 1997-11-26
US5543296A (en) 1996-08-06
ES2111047T3 (es) 1998-03-01
EP0520794A1 (de) 1992-12-30
CA2072314C (en) 2007-07-31
JP3898233B2 (ja) 2007-03-28
US5766888A (en) 1998-06-16
DK0520794T3 (da) 1998-04-27
CA2072314A1 (en) 1992-12-27
JPH05269000A (ja) 1993-10-19
GR3026153T3 (en) 1998-05-29
DE69223284T2 (de) 1998-06-25
AU662906B2 (en) 1995-09-21
AU1846592A (en) 1993-01-07

Similar Documents

Publication Publication Date Title
DE69223284D1 (de) Methoden zur Bestimmung von Krebsmetastasen mittels Nukleinsäuren-Amplifikation
DE69213112D1 (de) Verbesserte Methoden zur Nukleinsäure-Amplifizierung
DE3873842D1 (de) Verfahren zur gen-amplifikation.
DE3774488D1 (de) Verfahren zur routen-festlegung.
DE69122346D1 (de) Amplifikation von Midivariant-DNS-Templaten
DE3875667D1 (de) Menschliche papillomavirusnukleinsaeureproben.
DE3854176D1 (de) Verfahren zur Genkartierung.
DE3882847D1 (de) Verfahren zur unmittelbaren bestimmung physikalischer eigenschaften von kohlenwasserstoffprodukten.
DE3851910D1 (de) Abtastsystem zur Bestimmung der Fluoreszenz.
DE3882737D1 (de) Zweiphasige wellenformen zur defibrillation.
DE69114869D1 (de) Verfahren zur Bestimmung des Profils von Reifen.
DE68922772D1 (de) Verfahren zur Zeichenkettenermittlung.
DE3686376D1 (de) Signalverarbeitungsverfahren zur bestimmung der basissequenz von nukleinsaeure.
DE3751366D1 (de) Signalverarbeitungsmethode zur Bestimmung des Grundaufbaus von Nukleinsäuren.
DE3681034D1 (de) Verfahren zur oxydehydrierung von ethan.
DE3787880D1 (de) Verfahren zur Acrylamid-Aufspaltung.
DE3763340D1 (de) Verfahren zur bestimmung der beschmutzungs-tendenz von kohlenwasserstoffen.
DE59712415D1 (de) Verfahren zur amplifikation von nukleinsäure
DE3585238D1 (de) Verfahren zur bestimmung des reduzierten zustands von nicotinamid-adenin-dinukleotid.
DE3687958D1 (de) Verfahren zur verbesserung der bindung von getuftetem pol von textilen belaegen.
DE3784039D1 (de) Verfahren zur acrylamid-aufspaltung.
DE3874510D1 (de) Verfahren zur stabilisierung von hydroisomeraten.
DE69026611D1 (de) Verfahren zur Bestimmung von Fruktosaminen
DE3678990D1 (de) Verfahren zur bestimmung von bilirubin.
DE3674535D1 (de) Signalverarbeitungsmethode zur bestimmung des grundaufbaus von nukleinsaeuren.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation